Drug Details

General Information of the Drug (ID: DR0688)
Name
Dipyridamole
Synonyms
dipyridamole; 58-32-2; Dipyridamol; Dipyridamine; Persantin; Dipyudamine; Persantine; Curantyl; Stimolcardio; Cardoxin; Kurantil; Stenocardil; Cardioflux; Dipiridamol; Dipyridan; Peridamol; Anginal; Apricor; Coribon; Corosan; Coroxin; Stenocardiol; Agilease; Chilcolan; Justpertin; Permiltin; Piroan; Cleridium 150; Coronarine; Gulliostin; Prandiol; Natyl; Prandiol 75; Usaf Ge-12; Dypyridamol; 2,2',2'',2'''-((4,8-Di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetraethanol; Dipyridamolum; RA 8; RA-8; Dipyridamole (Persantine); C24H40N8O4; UNII-64ALC7F90C; NSC 515776; NSC-515776; MLS000028420; Cleridium; CHEMBL932; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; Iv Persantine; SMR000058382; 64ALC7F90C; CHEBI:4653; Cardoxil; Pyrimido(5,4-d)pyrimidine, 2,6-bis(bis(2-hydroxyethyl)amino)-4,8-dipiperidino-; MFCD00010555; NSC515776; 2-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)pyrimido[5,4-d][1,3]diazin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol; 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol; Ethanol, 2,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-; CAS-58-32-2; NCGC00015385-12; Dypyridamole; Coridil; Protangix; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; DSSTox_CID_20668; DSSTox_RID_79531; DSSTox_GSID_40668; 2,2',2'',2'''-((4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetrakis(ethan-1-ol); 2,2',2'',2'''-{[4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl]dinitrilo}tetraethanol; Ethanol, 2,2',2'',2'''-((4,8-di-1-piperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis-; Ethanol,2,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-; Dipiridamol [INN-Spanish]; Dipyridamolum [INN-Latin]; Permole; Persantine (TN); (3E)-3-[[(1S,4aS,8aS)-Decahydro-5,5,8a-trimethyl-2-methylene-1-naphthalenyl]methylene]dihydro-5-methoxy-2(3H)3-[(1E)-2-[(1S,4aS,8aS)-Decahydro-5,5,8a-trimethyl-2-methylene-1-naphthalenyl]ethenyl]furan; (+)-Coronarin E-furanone; Coronarin D methyl ethe; 2,2',2'',2'''-((4,8-Di(piperidin-1-yl)pyrimido[5,4-d]-pyrimidine-2,6-diyl)bis(azanetriyl))tetraethanol; SR-01000003065; EINECS 200-374-7; BRN 0068373; Dipridacot; Prestwick_145; Dipyridamole [USAN:USP:INN:BAN:JAN]; Spectrum_001004; Tocris-0691; Opera_ID_494; Prestwick0_000142; Prestwick1_000142; Prestwick2_000142; Prestwick3_000142; Spectrum2_000972; Spectrum3_000402; Spectrum4_000522; Spectrum5_000839; Lopac-D-9766; UPCMLD-DP072; D 9766; cid_3108; 2,2',2'',2'''-((4,8-Dipiperidinopyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetraethanol; Lopac0_000464; SCHEMBL16119; BSPBio_000244; BSPBio_001554; BSPBio_001924; KBioGR_001123; KBioSS_001484; 4-26-00-03840 (Beilstein Handbook Reference); MLS001076306; MLS001333724; MLS002548866; DivK1c_000696; SPECTRUM1500259; SPBio_001003; SPBio_002183; BPBio1_000270; GTPL4807; DTXSID6040668; Thymidine,6-dihydro-6-methoxy-; UPCMLD-DP072:001; BDBM23620; Dipyridamole (JP17/USP/INN); HMS502C18; IZEKFCXSFNUWAM-UHFFFAOYSA-; KBio1_000696; KBio2_001484; KBio2_004052; KBio2_006620; KBio3_001144; B01AC07; NINDS_000696; BCPP000256; HMS1568M06; HMS1791N16; HMS1920I10; HMS1989N16; HMS2089N15; HMS2091O18; HMS2095M06; HMS2232E19; HMS3259C03; HMS3261M10; HMS3266J17; HMS3371J03; HMS3402N16; HMS3411B03; HMS3655I20; HMS3675B03; HMS3712M06; HMS3742O03; HMS3867F13; Pharmakon1600-01500259; ZINC643046; AMY40468; BCP26947; EBD20789; HY-B0312; Tox21_110133; Tox21_500464; 2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; ANW-49242; BBL027781; CCG-40190; NSC756743; s1895; STL377790; AKOS000509426; Tox21_110133_1; BCP9000613; DB00975; Dipyridamole, >=98% (TLC), powder; HS-0041; LP00464; MCULE-3112669573; MP-0582; NC00448; NSC-619103; NSC-756743; SDCCGSBI-0050449.P005; VA10749; IDI1_000696; SMP2_000208; NCGC00015385-01; NCGC00015385-02; NCGC00015385-03; NCGC00015385-04; NCGC00015385-05; NCGC00015385-06; NCGC00015385-07; NCGC00015385-08; NCGC00015385-09; NCGC00015385-10; NCGC00015385-11; NCGC00015385-13; NCGC00015385-14; NCGC00015385-15; NCGC00015385-16; NCGC00015385-18; NCGC00015385-29; NCGC00023914-02; NCGC00023914-04; NCGC00023914-05; NCGC00023914-06; NCGC00023914-07; NCGC00023914-08; NCGC00023914-09; NCGC00023914-10; NCGC00023914-11; NCGC00261149-01; 2-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)-[1,3]diazino[5,4-d]pyrimidin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol; 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-bis(1-piperidyl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol; AC-18100; AC-30804; AK-76609; Ethanol, 2,2',2'',2'''-((4,8-dipiperidinopyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetra-; H843; NCI60_005689; ST078856; SBI-0050449.P004; 2,8-dipiperidinopyrimido[5,4-d]pyrimidine; AB0013300; AB00051974; B1933; EU-0100464; FT-0603242; SW196456-3; W1467; EN300-70723; BIM-0050449.0001; D00302; J10379; 54290-EP2277865A1; 54290-EP2298773A1; 54290-EP2305653A1; 54290-EP2308562A2; AB00051974-18; AB00051974-19; AB00051974_20; AB00051974_21; A828156; Q419374; SR-01000003065-2; SR-01000003065-4; SR-01000003065-5; SR-01000003065-7; W-105400; BRD-K86301799-001-04-1; BRD-K86301799-001-19-9; BRD-K86301799-001-24-9; Z1259192074; Dipyridamole, British Pharmacopoeia (BP) Reference Standard; Dipyridamole, European Pharmacopoeia (EP) Reference Standard; Dipyridamole, United States Pharmacopeia (USP) Reference Standard; Pyrimido(5, 2,6-bis[bis(2-hydroxyethyl)amino]-4,8-diperidino-; 2,2'',2'''-[4,8-Dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl]dinitrilotetraethanol; 2,2',2'',2'''-(4,8-Dipiperidinopyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilotetraethanol; 2-[[2-(bis(2-hydroxyethyl)amino)-4,8-di(piperidin-1-yl)pyrimido[6,5-e]pyrimidin-; Dipyridamole for peak identification, European Pharmacopoeia (EP) Reference Standard; Ethanol,2',2'',2'''-(4,8-dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetra-; WLN: T66 BN DN GN INJ CCN HCN E- AT6NTJ B2Q F2Q& J- AT6NTJ B2Q F2Q; 2,2',2'',2'''-(4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl)tetraethanol; 2,2',2'',2'''-[(4,8-dipiperidin-1-ylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetraethanol; 2,2',2'',2'''-[(4,8-Dipiperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetraethanol; 2,2',2'',2'''-[(4,8-Dipiperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakisethanol; 2-({6-[bis(2-hydroxyethyl)amino]-4,8-dipiperidylpyrimidino[5,4-d]pyrimidin-2-y l}(2-hydroxyethyl)amino)ethan-1-ol; 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-bis(1-piperidinyl)-6-pyrimido[5,4-d]pyrimidinyl]-(2-hydroxyethyl)amino]ethanol; 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol;; Ethanol, 2,2',2'',2'''-(4,8-dipiperidinopyrimido(5,4-d)pyrimidine-2,6-diyldinitrilo)tetra-; Ethanol, 2,2',2',2'''-((4,8-di-1-iperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis-; Ethanol,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-; Ethanol,2',2'',2'''-[(4,8-dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetra-
    Click to Show/Hide
Molecular Type
Small molecule
Disease Hypertension [ICD-11: BA00] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absorption
The absorption of drug is 70%
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability
Clearance
The clearance of drug is 2.3-3.5 mL/min/kg
Elimination
0.1% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 40 minutes
Metabolism
The drug is metabolized via the hepatic
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 13.211 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.009%
Vd
The volume of distribution (Vd) of drug is 1-2.5 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 0.007 mg/mL
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C24H40N8O4
PubChem CID
3108
Canonical SMILES
C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
InChI
1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
InChIKey
IZEKFCXSFNUWAM-UHFFFAOYSA-N
CAS Number
CAS 58-32-2
ChEBI ID
CHEBI:4653
TTD Drug ID
D0F9GE
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Vincristine      Catharanthus roseus     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model MOLT-3 CVCL_0624 Adult T acute lymphoblastic leukemia Homo sapiens
ML1 CVCL_0436 Adult acute myeloid leukemia Homo sapiens
BL-TH Burkitt's lymphoma Homo sapiens
                    Experimental
                    Result(s)		 Dipyridamole and vincristine combination showed synergistic inhibitory effects on the growth of human leukaemia and lymphoma cell lines.
Target and Pathway
Target(s) Phosphodiesterase 5A (PDE5A)  Molecule Info  [3]
KEGG Pathway Purine metabolism Click to Show/Hide
2 cGMP-PKG signaling pathway
NetPath Pathway TGF_beta_Receptor Signaling Pathway Click to Show/Hide
Reactome cGMP effects Click to Show/Hide
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4807).
Reference 2 Synergistic inhibitory effects of dipyridamole and vincristine on the growth of human leukaemia and lymphoma cell lines. Br J Cancer. 1987 Oct;56(4):413-7.
Reference 3 Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
 Download Picture         KEGG Link